ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults Plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults.